Journal
PATHOLOGY RESEARCH AND PRACTICE
Volume 215, Issue 5, Pages 873-879Publisher
ELSEVIER GMBH
DOI: 10.1016/j.prp.2019.01.030
Keywords
Epiregulin; Gastric cancer; Prognosis
Categories
Funding
- National Natural Science Foundation of China [81201596, 81,773,100]
- Special Fund of Clinical Medicine in Jiangsu Province [BL2013038]
- AoYang Cancer Research Foundation [AYCR14-001]
- Priority Academic Program Development of Jiangsu Higher Education Institutions, grant of Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine
- Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine
Ask authors/readers for more resources
Epiregulin (EREG) is a novel family member of EGF-like ligands and have elevated expression in a variety of human cancers. EREG expression promotes tumor progression and metastasis and reduces patient survival. However, the expression of EREG and its prognostic value are not clear in gastric cancer (GC). We assessed EREG mRNA and protein expression in GC tissues from Chinese patients using quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemical staining of tissue microarray, and analyzed the correlation between the level of EREG expression and patient clinical characteristics and prognosis. We found that EREG expression was significantly higher in GC tissues than in matched adjacent noncancerous tissues. High EREG protein expression in GC was significantly associated with TNM stage including tumor size, lymph node metastases and distant metastases as well as poor overall survival. These finding demonstrate that EREG is an independent prognostic biomarker for GC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available